|
End-of-day quote
Korea S.E.
2026-08-25
|
5-day change | 1st Jan Change | ||
| 189,600.00 KRW | -2.27% |
|
-3.02% | +9.99% |
| 08-25 | Celltrion Launches Omlyclo 300 Mg Strength In Key European Markets | CI |
| 08-23 | Celltrion Submits Marketing Application for Keytruda Biosimilar in South Korea | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CELLTRION, INC. | Other Biotechnology & Medical Research | -2.27% | -3.02% | +9.99% | +14.22% | -18.22% | 32.87B |  | | |
- Stock Market
- Stocks
- A068270 Stock
- Charts Celltrion, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
